TherapeuticsMD (TXMD) Cash from Discontinued Operations (2010 - 2026)

TherapeuticsMD has reported Cash from Discontinued Operations for 6 years, with the latest figure at 8000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Discontinued Operations rose 38.46% year-over-year to 8000.0; the trailing twelve-month figure through Mar 2026 stood at 25000.0 (up 96.38% YoY), and the FY2025 full-year result was 30000.0, up 93.15% from the prior year.
• Cash from Discontinued Operations for Q1 2026 stood at 8000.0, down from 7000.0 in the prior quarter.
• The five-year high for Cash from Discontinued Operations was 136529000.0 in Q2 2022, with the low at 23368000.0 in Q1 2023.
• Historically, Cash from Discontinued Operations has averaged 10874176.47 across 5 years, with a median of 13000.0 in 2025.
• The largest YoY upside for Cash from Discontinued Operations was 141.23% in 2025 against a maximum downside of 105.42% in 2025.
• TherapeuticsMD's Cash from Discontinued Operations stood at 92770000.0 in 2022, then tumbled by 103.11% to 2881000.0 in 2023, then soared by 99.83% to 5000.0 in 2024, then sank by 40.0% to 7000.0 in 2025, then decreased by 14.29% to 8000.0 in 2026.
• The last three Cash from Discontinued Operations figures came in at 8000.0 (Q1 2026), 7000.0 (Q4 2025), and 47000.0 (Q3 2025), per Business Quant data.